Phaseline

Targets › FCGR2B

FCGR2B (Low affinity immunoglobulin gamma Fc region receptor II-b): drug programs, companies and trials

4 programs from 4 companies in 10 trials: 6 Phase 2, 2 Phase 3, 2 Phase 1; Neurology, Other, Hematology; next expected readout Dec 2026.

Receptor for the Fc region of complexed or aggregated immunoglobulins gamma. Low affinity receptor. (UniProt, P31994)

Open in Phaseline: the race on FCGR2B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zenas BioPharma (USA)Obexelimab
B-lymphocyte antigen CD19 inhibitor; Low affinity immunoglobulin gamma Fc region receptor II-b inhibitor
CD19, FCGR2BPhase 3Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis; Systemic Lupus ErythematosusDec 2026
Nuvig TherapeuticsNVG-2089
FcγRIIB agonist (IVIg mimetic)
FCGR2BPhase 2Chronic Inflammatory Demyelinating Polyneuropathy; Immune Thrombocytopenia (ITP)Jun 2027
argenxARGX-117
FcγRIIB agonist / IgG4-Fc fusion protein
FCGR2BPhase 2Multifocal Motor Neuropathy (MMN); Delayed Graft FunctionSep 2029
BioInvent InternationalBI-1206
anti-CD32B monoclonal antibody
FCGR2BPhase 1Indolent B-Cell Non-Hodgkin Lymphoma; Solid Tumor, AdultSep 2027

Conditions

Multifocal Motor Neuropathy (MMN) (1) Delayed Graft Function (1) Chronic Inflammatory Demyelinating Polyneuropathy (1) Immune Thrombocytopenia (ITP) (1) Warm Autoimmune Hemolytic Anemia (1) IgG4 Related Disease (1) Relapsing Multiple Sclerosis (1) Systemic Lupus Erythematosus (1) Indolent B-Cell Non-Hodgkin Lymphoma (1) Solid Tumor, Adult (1)

Modalities

antibody (2), protein or peptide (1), small molecule (1)

Companies

argenx (1) Nuvig Therapeutics (1) Zenas BioPharma (USA) (1) BioInvent International (1)

Related targets

CD19 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.